Poseida Therapeutics Acquired by Roche at 215% Premium
Deal News | Nov 26, 2024 | Aescap Venture Management BV
In a significant transaction, Roche has announced its acquisition of Poseida Therapeutics, a portfolio company of Aescap Genetics, for $9 per share. This acquisition price represents a premium of over 215% compared to the previous day's closing share price of $2.86. As part of the agreement, Poseida shareholders will also receive contingent value rights (CVR) valued at $4, payable in three installments of $2, $1, and $1. This acquisition highlights Roche's strategic interest in bolstering its therapeutic offerings, and the considerable premium underscores the value it sees in Poseida's potential. Aescap Venture Management BV, the private equity firm involved, benefits from the premium valuation provided by Roche.
Sectors
- Pharmaceuticals & Biotechnology
- Private Equity & Venture Capital
Geography
- United States – Poseida Therapeutics is based in the United States, making it a relevant geography for the acquisition.
- Switzerland – Roche, the acquiring company, is headquartered in Switzerland, highlighting this geography's relevance.
Industry
- Pharmaceuticals & Biotechnology – The article involves Roche, a leading pharmaceutical company, acquiring Poseida Therapeutics, which operates in the biotechnology sector.
- Private Equity & Venture Capital – Aescap Venture Management BV, a private equity firm, manages Aescap Genetics' which held Poseida Therapeutics in its portfolio.
Financials
- 9 – Price per share paid by Roche for Poseida Therapeutics.
- 2.86 – Poseida Therapeutics' closing share price the day before the acquisition announcement.
- 4 – Contingent value rights (CVR) total per share offered to Poseida's shareholders.
- 215% – Premium paid by Roche over the previous day's closing share price for Poseida Therapeutics.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Roche | Acquirer | Company | A global healthcare company that seeks to acquire and develop new therapeutic solutions. |
| Poseida Therapeutics | Target | Company | A biopharmaceutical company focused on translating its proprietary gene engineering technologies into therapies. |
| Aescap Venture Management BV | Private Equity Firm | Company | The PE firm managing the investment in Poseida Therapeutics through Aescap Genetics. |
| Aescap Genetics | Seller | Company | Aescap Genetics held Poseida Therapeutics in its portfolio. |